Industrial bioscience firm Amyris (Emeryville, California) announced on Monday that it has entered into its first product development and production agreement with DSM.
The agreement covers an undisclosed food and nutrition molecule for which DSM is a major market provider. DSM will fund technology development, and Amyris will scale and supply the ingredient in the long-term.
The agreement is expected to be the first of many such collaborations, Amyris says. In May, DSM made an initial equity investment in Amyris of $25 million for a shareholding of about 12%. Subject to certain conditions, DSM could invest an additional $25 million in the company within 90 days of the first tranche if approved by DSM’s board. As part of the deal, DSM and Amyris agreed to collaborate on a number of short- to medium-term product development and production opportunities using Amyris’s yeast-based strain engineering platform.
By Rebecca Coons
Source: Chemical Week
Saudi Industrial Investment Group (SIIG; Riyadh) and National Petrochemical Co. (Petrochem; Jubail, Saudi Arabia) say they have started talks over a potential merger of the two companies. SIIG and Petrochem […]
Solvay has launched its Peroxides for the Future (P4F) program, a multi-year plan to adapt its peroxides industrial footprint in EMEA and make product available where customers need it most. […]
INEOS Styrolution and Trinseo, global leaders in the manufacturing of polystyrene and other styrenic materials, announced today that they are advancing plans to build the first-of-its-kind polystyrene recycling plant based […]